Niraparib maintenance therapy in advanced ovarian cancer

被引：0
|
作者：
Lorenz, Judith
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2025年 / 85卷 / 03期
关键词：
D O I：
10.1055/a-2510-8331
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
The randomized PRIMA/ENGOT-OV26/GOG-3012 study showed that patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based first-line chemotherapy benefit from maintenance therapy with the PARP inhibitor niraparib (PARP: poly[ADP]-ribose polymerase) in terms of progression-free survival. The researchers are now reporting the final analysis of the data on overall survival.
引用
收藏
页码：237 / 237
页数：1
相关论文
共 50 条
  • [1] Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
    Arnold Lee
    Targeted Oncology, 2021, 16 : 839 - 845
  • [2] Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
    Lee, Arnold
    TARGETED ONCOLOGY, 2021, 16 (06) : 839 - 845
  • [3] NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer
    Sghaier, Syrine
    Corbaux, Pauline
    Ray-Coquard, Isabelle
    Lim, Myong Cheol
    Hasegawa, Kosei
    Van Nieuwenhuysen, Els
    Gonzalez, Antonio
    Raspagliesi, Francesco
    Freyer, Gilles
    FUTURE ONCOLOGY, 2023, 19 (25) : 1715 - 1727
  • [4] Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
    Arnold Lee
    Targeted Oncology, 2022, 17 : 89 - 89
  • [5] Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases
    Gray, Simon
    Khor, Xiao Ying
    Yiannakis, Dennis
    BMJ CASE REPORTS, 2019, 12 (08)
  • [6] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    Mirza, M. R.
    Monk, B. J.
    Herrstedt, J.
    Oza, A. M.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J. A.
    Lorusso, D.
    Vergote, I.
    Ben-Baruch, N. E.
    Marth, C.
    Madry, R.
    Christensen, R. D.
    Berek, J. S.
    Dorum, A.
    Tinker, A. V.
    du Bois, A.
    Gonzalez-Martin, A.
    Follana, P.
    Benigno, B.
    Rosenberg, P.
    Gilbert, L.
    Rimel, B. J.
    Buscema, J.
    Balser, J. P.
    Agarwal, S.
    Matulonis, U. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2154 - 2164
  • [7] Niraparib maintenance therapy in early expanded access ovarian cancer patients
    Nieto Gomez, P.
    Tauste Hernandez, B.
    Rodriguez Delgado, A.
    Portillo Haro, S. F. D. A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 285 - 285
  • [8] Increase in creatinine levels associated with niraparib maintenance therapy in ovarian cancer
    Takahashi, Yoshifumi
    Taguchi, Masahiro
    Tamura, Kohei
    Shinohara, Miki
    Koyanagi, Takahiro
    Takahashi, Suzuyo
    Taneichi, Akiyo
    Takei, Yuji
    Saga, Yasushi
    Fujiwara, Hiroyuki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (03) : 501 - 507
  • [9] Niraparib maintenance in newly diagnosed advanced ovarian cancer - review and case series
    Tyszka, Martyna
    Stec, Rafal
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (06): : 413 - 418
  • [10] Real-world treatment of niraparib as maintenance therapy in patients newly diagnosed advanced ovarian cancer in Japan
    Shimada, Muneaki
    Kuwahara, Yuki
    Kuwabara, Hiroyo
    Kato, Ai
    Tabata, Tsutomu
    ANNALS OF ONCOLOGY, 2023, 34 : S1440 - S1440
12345